Li Su1,2, Lawrence Hayes1, Soteris Soteriades1, Guy Williams3, Susannah A E Brain4, Michael J Firbank5, Giulia Longoni1, Robert J Arnold1, James B Rowe6,7, John T O'Brien1. 1. Department of Psychiatry, University of Cambridge School of Clinical Medicine, Cambridge, UK. 2. China-UK Centre for Cognition and Ageing Research, Faculty of Psychology, Southwest University, Chongqing, China. 3. Wolfson Brain Imaging Centre, University of Cambridge, School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK. 4. Oxford University Hospitals NHS Trust, Windmill Road, Oxford, UK. 5. Institute of Neuroscience and Newcastle University Institute for Ageing, Newcastle University Campus for Ageing and Vitality, Newcastle upon Tyne, UK. 6. Department of Clinical Neurosciences, Cambridge University, UK. 7. MRC Cognition and Brain Sciences Unit, Cambridge, UK.
Abstract
BACKGROUND: Alzheimer's disease (AD) is associated with atrophy in entorhinal cortex (ERC), the hippocampus, and its subfields Cornu Ammonis 1 (CA1) and subiculum, which predict conversion from mild cognitive impairment (MCI) to clinical AD. The stratum radiatum, lacunosum, and moleculare (SRLM) are also important gateways involving ERC and CA1, which are affected by early AD pathology. OBJECTIVE: To assess whether the SRLM is affected in MCI and AD. METHODS: In this proof-of-concept study, 27 controls, 13 subjects with AD, and 22 with MCI underwent 3T MRI. T1 maps were used for whole-hippocampal volumetry, T2 maps were segmented for hippocampal subfield areas, entorhinal cortex and subiculum thickness, and evaluated for SRLM integrity. RESULTS: Significant CA1 atrophy and subiculum thinning were found in both AD and MCI compared to similarly aged controls. However, SRLM integrity was only significantly reduced in AD but not in MCI compared to controls. There were no significant differences in other hippocampal subfields (CA2, CA3/dentate gyrus) or ERC thickness between the groups. Finally, CA1 and CA3/DG areas and SRLM clarity were correlated with clinical and cognitive measurements of disease severity. CONCLUSION: Although this study was cross sectional, it suggests a progression of specific subfield changes from MCI to established AD that is associated with the reduced integrity of SRLM, which may reflect more widespread hippocampal involvement as the disease progresses and the relative preservation of SRLM in MCI. These results provide new MRI biomarkers for disease staging and understanding of the neurobiology in AD.
BACKGROUND: Alzheimer's disease (AD) is associated with atrophy in entorhinal cortex (ERC), the hippocampus, and its subfields Cornu Ammonis 1 (CA1) and subiculum, which predict conversion from mild cognitive impairment (MCI) to clinical AD. The stratum radiatum, lacunosum, and moleculare (SRLM) are also important gateways involving ERC and CA1, which are affected by early AD pathology. OBJECTIVE: To assess whether the SRLM is affected in MCI and AD. METHODS: In this proof-of-concept study, 27 controls, 13 subjects with AD, and 22 with MCI underwent 3T MRI. T1 maps were used for whole-hippocampal volumetry, T2 maps were segmented for hippocampal subfield areas, entorhinal cortex and subiculum thickness, and evaluated for SRLM integrity. RESULTS: Significant CA1 atrophy and subiculum thinning were found in both AD and MCI compared to similarly aged controls. However, SRLM integrity was only significantly reduced in AD but not in MCI compared to controls. There were no significant differences in other hippocampal subfields (CA2, CA3/dentate gyrus) or ERC thickness between the groups. Finally, CA1 and CA3/DG areas and SRLM clarity were correlated with clinical and cognitive measurements of disease severity. CONCLUSION: Although this study was cross sectional, it suggests a progression of specific subfield changes from MCI to established AD that is associated with the reduced integrity of SRLM, which may reflect more widespread hippocampal involvement as the disease progresses and the relative preservation of SRLM in MCI. These results provide new MRI biomarkers for disease staging and understanding of the neurobiology in AD.
Authors: Liana G Apostolova; Rebecca A Dutton; Ivo D Dinov; Kiralee M Hayashi; Arthur W Toga; Jeffrey L Cummings; Paul M Thompson Journal: Arch Neurol Date: 2006-05
Authors: G Lace; G M Savva; G Forster; R de Silva; C Brayne; F E Matthews; J J Barclay; L Dakin; P G Ince; S B Wharton Journal: Brain Date: 2009-03-24 Impact factor: 13.501
Authors: Richard Camicioli; M Milar Moore; Anthony Kinney; Elizabeth Corbridge; Kathryn Glassberg; Jeffrey A Kaye Journal: Mov Disord Date: 2003-07 Impact factor: 10.338
Authors: Li Liu; Valerie Drouet; Jessica W Wu; Menno P Witter; Scott A Small; Catherine Clelland; Karen Duff Journal: PLoS One Date: 2012-02-01 Impact factor: 3.240
Authors: Jared Rowley; Vladimir Fonov; Ona Wu; Simon Fristed Eskildsen; Dorothee Schoemaker; Liyong Wu; Sara Mohades; Monica Shin; Viviane Sziklas; Laksanun Cheewakriengkrai; Amir Shmuel; Alain Dagher; Serge Gauthier; Pedro Rosa-Neto Journal: PLoS One Date: 2013-09-27 Impact factor: 3.240
Authors: María F Zappa Villar; Juliette López Hanotte; Joaquín Pardo; Gustavo R Morel; Guillermo Mazzolini; Mariana G García; Paula C Reggiani Journal: Mol Neurobiol Date: 2019-08-10 Impact factor: 5.590
Authors: María F Zappa Villar; Juliette López Hanotte; Eugenia Falomir Lockhart; Lucía S Trípodi; Gustavo R Morel; Paula C Reggiani Journal: J Neural Transm (Vienna) Date: 2018-09-22 Impact factor: 3.575
Authors: Teresa A Milner; Ryan X Chen; Diedreanna Welington; Batsheva R Rubin; Natalina H Contoreggi; Megan A Johnson; Sanoara Mazid; Jose Marques-Lopes; Roberta Marongiu; Michael J Glass Journal: Learn Mem Date: 2022-09-06 Impact factor: 2.699
Authors: Maria-Eleni Dounavi; Coco Newton; Natalie Jenkins; Elijah Mak; Audrey Low; Graciela Muniz-Terrera; Guy B Williams; Brian Lawlor; Lorina Naci; Paresh Malhotra; Clare E Mackay; Ivan Koychev; Karen Ritchie; Craig W Ritchie; Li Su; John T O'Brien Journal: J Neurol Date: 2022-03-13 Impact factor: 6.682